Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 30 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Clinical Trial Support Services

Active

Grant

Response Deadline11/10/2026, 05:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Clinical Trial Support Services subcontract for the National Institutes of Health under the Department of Health and Human Services focuses on the administrative and operational management of clinical trials for prime contractors operating NIH REACH Hubs. The scope of work includes managing patient recruitment, IRB coordination, clinical site management, and data collection. To qualify, providers must possess Good Clinical Practice certification and demonstrated experience with NIH-defined clinical trials and data management systems. Key deliverables for this engagement include patient data sets, clinical trial reports, and regulatory submission packages. The opportunity was posted on September 24, 2026, with a response deadline of November 10, 2026. This subcontract falls under NAICS code 541714.

General Info

NIH subcontract for clinical trial management, recruitment, and data services; deadline November 10, 2026.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of RFA-OD-27-009.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedSep 24

subcontract

Response DeadlineNov 10

Submission deadline

Response Deadline

11/10/2026, 05:00:00 AM UTCin about 2 months

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Performs administrative and operational management of clinical trials for prime contractors operating NIH REACH Hubs. Manages patient recruitment, IRB coordination, data collection, and clinical site management. Requires GCP (Good Clinical Practice) certification and experience with NIH-defined clinical trials and data management systems. Delivers clinical trial reports, patient data sets, and regulatory submission packages.

Similar Contracts

Same NAICS industry code

UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)

Solicitation # ARPA-H-SOL-26-162

The Advanced Research Projects Agency for Health (ARPA-H) has issued Innovative Solutions Opening (ISO) ARPA-H-SOL-26-162 for the UNifying Imaging with QUantum Entanglement (UNIQUE) Program. This merit-based solicitation seeks to develop new biomedical imaging capabilities by exploring quantum-derived observables, such as photon correlation signatures and positronium-sensitive interactions, to reveal biological information invisible to current imaging technologies. The agency anticipates awarding multiple Other Transaction (OT) Agreements to proposers who can demonstrate highly innovative and feasible technical approaches. The submission process is divided into two stages, with solution summaries due October 30, 2026, and full proposals due by December 15, 2026. Full proposals must be submitted via the ARPA-H Solutions portal in three volumes: Technical and Management, Cost, and Administrative and Policy Requirements. Evaluation is based on technical innovation and feasibility, proposer capabilities, relevance to the ARPA-H mission, and cost. For-profit organizations that are not small businesses under NAICS 541714 are required to provide a meaningful cost share. Strict compliance is required regarding research security, including disclosures of foreign influence and prohibitions on participation in Malign Foreign Talent Recruitment Programs. Additionally, the program excludes proposals that offer only incremental improvements or utilize human embryos or fetal tissue. Awardees will be expected to provide monthly status reports and participate in semi-annual in-person review meetings, with all key personnel expected to be onboard within 60 days of the award.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

HUBBLE DRAFT Program Announcement (PA)

Solicitation # DARPA-PA-26-10_DRAFT

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is issuing a presolicitation notice for the HUBBLE program, which aims to develop an in-silico capability for mapping all protein-protein interactions. The goal is to create a comprehensive human interactome hypercatalog, demonstrating its utility by identifying novel diagnostic and therapeutic targets for conditions such as traumatic brain injury. The program is structured in two phases, with Phase 1 lasting 12 months and Phase 2 lasting 18 months. Key deliverables include the development of PPI fingerprinting capabilities, the capture of a minimal interactome for mild traumatic brain injury, and the generation of a massive PPI hypercatalog benchmarked against DARPA-provided experimental datasets. Awards will be issued as Other Transactions for Research under 10 U.S.C. 4021, meaning they are not subject to the Federal Acquisition Regulation or the Defense Federal Acquisition Regulations Supplement. Eligible applicants include large and small businesses, universities, research institutions, and nontraditional defense contractors. Proposers must be registered in the System for Award Management and maintain CMMC Level 1 compliance. Evaluation is based on technical comprehension, technical ability, and the reasonableness of the cost rough order of magnitude. Submissions must be made via DARPA's Broad Agency Announcement Tool, and all abstracts must remain unclassified.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' Day

Solicitation # ARPA-H-SN-26-162

The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, has issued Special Notice ARPA-H-SN-26-162 to announce the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This initiative aims to establish a new biomedical imaging paradigm by utilizing quantum-derived observables, specifically entangled or quantum-correlated 511 keV photon pairs, to reveal disease biology that is currently invisible to existing technologies. The program is divided into two primary technical areas: the Imaging Core, which focuses on the physical systems and detectors required to generate and measure quantum-derived imaging contrast, and Quantum AI Interpretation and Fusion, which focuses on developing AI-driven reconstruction methods to integrate these observables into multidimensional imaging representations. This special notice serves as an informational alert and does not constitute a formal solicitation. It announces a hybrid Proposers Day scheduled for October 15, 2026, to prepare the scientific community for an upcoming Innovative Solutions Opening (ISO) expected by September 18, 2026. Interested parties are encouraged to submit a single capability slide via the UNIQUE Teaming Profile Form by September 22, 2026, to participate in lightning talks during the event. Technical inquiries are directed to Program Manager Wilfred Ngwa at UNIQUE@arpa-h.gov.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Request for Information (RFI) on Identifying Basic Research Challenges to Accelerate United States Biotechnology Leadership

Solicitation # 892431-26-RFI-0003

The Department of Energy Office of Science, under the Biological and Environmental Research program, issued Request for Information 892431-26-RFI-0003 on September 24, 2026. This RFI is intended for market research to identify critical basic research challenges and scientific bottlenecks necessary to transition from descriptive biology to predictive biosystems design. The initiative focuses on three primary science objectives: translating genetic code into biochemical functions, designing cells and metabolic pathways to control cellular operations, and developing multi-scale computational models to predict the performance of plants and microorganisms. The ultimate goal is to accelerate the production of bio-advantaged materials, chemicals, and fuels to strengthen United States biotechnology leadership. Interested stakeholders are requested to provide succinct responses not exceeding two pages in a machine-readable PDF format by October 15, 2026. Submissions should address near-term scientific bottlenecks occurring within three to five years, missing capabilities for scaling biosystems design, high-priority industrial application areas, and effective models for public-private partnerships. Responses must include the organization name and a point of contact and should be submitted to the DOE Biotech Input email with the specified subject line. This RFI is for planning purposes and does not constitute a solicitation or a promise to issue a contract; furthermore, the DOE will maintain unlimited rights to all submitted information, and no proprietary or classified data should be included.

Department Of Energy

POSTED

DEADLINE

Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.

National Institutes Of Health

POSTED

DEADLINE

Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.

National Institutes Of Health

POSTED

DEADLINE

The Role of the Innate Immune System in the Pathogenesis of Type 1 DiabetesThe National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting a grant opportunity to investigate the role of the innate immune system in the initiation of Type 1 Diabetes. Funded by the Special Statutory Funding Program for Type 1 Diabetes Research, this initiative seeks to identify genetic and environmental causes of the disease by examining how innate immune components interact with beta cells and pancreatic tissues. The program emphasizes the use of new approach methodologies to determine the timing and impact of environmental triggers that activate these immune pathways. The primary objective is to improve the early identification of high-risk individuals and develop future prevention and therapeutic strategies. This effort is conducted under the authority of the Public Health Service Act and relevant federal regulations. Interested parties can contact the RISP-T1D point of contact for further information regarding this forecast.

National Institutes Of Health

POSTED

DEADLINE

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

Solicitation # RFA-OD-27-009

The National Institutes of Health is offering a limited competition funding opportunity under solicitation RFA-OD-27-009 to renew the Research Evaluation and Commercialization Hub (REACH) program. This initiative aims to accelerate the translation of academic biomedical discoveries into practical products that enhance public health and patient care by funding the creation of academic entrepreneurship Hubs. These Hubs will provide innovators with essential seed funding, mentorship, and resources to support proof-of-concept work and product development for high-priority technologies aligned with the NIH mission. Selected Hubs will operate as a consortium to provide infrastructure for identifying promising technologies, funding for product definition studies, and access to specialized expertise in regulatory, legal, business, and project management areas. A key component of the program is the development of entrepreneurship skills and the establishment of public-private partnerships to secure non-federal funding. Eligible organizations must submit their applications by November 10, 2026, and all submissions will undergo a standard peer-review process to determine merit for funding.

National Institutes Of Health

POSTED

DEADLINE

in about 2 months

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

Solicitation # RFA-OD-27-009

The National Institutes of Health Office of the Director is offering a limited competition funding opportunity under solicitation RFA-OD-27-009 to renew the Research Evaluation and Commercialization Hub (REACH) program. This initiative aims to accelerate the translation of academic biomedical discoveries into tangible products that enhance public health and patient care by funding the creation of academic entrepreneurship Hubs. These Hubs will provide innovators with essential seed investment, mentorship in product development, and resources for proof-of-concept work to advance high priority technologies aligned with the NIH mission. Selected Hubs will operate as a consortium to establish infrastructure for identifying promising technologies and provide funding for product definition studies, such as prototype development and feasibility research. They will also offer expertise in regulatory, business, legal, and project management areas while fostering skills in entrepreneurship. Success in this program relies heavily on the establishment of public-private partnerships and the acquisition of non-federal funding. Eligible organizations must submit their applications by November 11, 2026, and will undergo a standard peer-review process to determine merit for funding.

National Institutes Of Health Office Of The Director

POSTED

DEADLINE

in about 2 months

Clinical/Biological Research ConsultantThis subcontract opportunity is for a Clinical/Biological Research Consultant to support prime contractors on Department of Defense SBIR/STTR Phase I projects. The selected consultant will design and execute research studies involving human or animal subjects within approved clinical environments or specialized laboratories, ensuring all work adheres to strict ethical and regulatory standards. Key deliverables include subject-specific research data and all necessary compliance documentation, with a mandatory requirement for IRB or IACUC approvals. The project is managed by the Office of the Secretary of Defense and is designated as a Total Small Business Set-Aside, requiring the contractor to have fewer than 500 employees. Falling under NAICS code 541714, the solicitation was posted on September 23, 2026, with a response deadline of October 7, 2026.

Office of the Secretary of Defense

POSTED

DEADLINE

Bio-Medical/Life Sciences SpecialistThis subcontract opportunity for a Bio-Medical/Life Sciences Specialist supports prime contractors on Department of War SBIR projects for the U.S. Air Force. The scope of work involves conducting research with human or animal subjects and recombinant DNA, which includes executing specific protocols for genetic research and clinical trials. To ensure fund release, the contractor must have all necessary institutional approvals and protocols established. The project requires the delivery of clinical data, trial results, and comprehensive regulatory compliance documentation. This is a total small business set-aside under the SBIR/STTR mandate for companies with fewer than 500 employees, falling under NAICS code 541714. The response deadline for this opportunity is October 7, 2026.

POSTED

DEADLINE

ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening

Solicitation # ARPA-H-SOL-26-165

The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS